BACKGROUND: Previous studies suggest that mitral valve replacement is comparable to repair in the elderly, and a national trend exists toward tissue valves. However, few direct comparison data are available, and this study evaluated the effects of patient age on risk-adjusted survival after mitral procedures. METHODS: From 1986 to 2006, 2,064 patients underwent isolated primary mitral operations (±CABG). Maximal follow-up was 20 years with a median of 5 years. Valve disease etiology was the following: degenerative, 864; ischemic, 450; rheumatic, 416; endocarditis, 98; and "other," 236. Overall, 58% had repair and 39% had concomitant coronary artery bypass grafting. Survival differences were evaluated with a Cox proportional hazards model that included baseline characteristics, valve disease etiology, and choice of repair versus replacement with tissue or mechanical valves. RESULTS: Baseline risk profiles generally were better for mechanical valves, and age was the most significant multivariable predictor of late mortality [hazard ratio = 1.4 per 10-year increment, Wald χ(2) = 32.7, p < 0.0001]. As compared with repair, risk-adjusted survival was inferior with either tissue valves [1.8, 27.6, <0.0001] or mechanical valves [1.3, 8.1, 0.0044], and no treatment interaction was observed with age (p = 0.18). At no patient age did tissue valves achieve equivalent survival to either repair or mechanical valves. CONCLUSIONS: Mitral repair is associated with better survival than valve replacement across the spectrum of patient age. If replacement is required, mechanical valves achieve better outcomes, even in the elderly. These data suggest that tissue valves should be reserved only for patients with absolute contraindications to anticoagulation who are not amenable to repair.
BACKGROUND: Previous studies suggest that mitral valve replacement is comparable to repair in the elderly, and a national trend exists toward tissue valves. However, few direct comparison data are available, and this study evaluated the effects of patient age on risk-adjusted survival after mitral procedures. METHODS: From 1986 to 2006, 2,064 patients underwent isolated primary mitral operations (±CABG). Maximal follow-up was 20 years with a median of 5 years. Valve disease etiology was the following: degenerative, 864; ischemic, 450; rheumatic, 416; endocarditis, 98; and "other," 236. Overall, 58% had repair and 39% had concomitant coronary artery bypass grafting. Survival differences were evaluated with a Cox proportional hazards model that included baseline characteristics, valve disease etiology, and choice of repair versus replacement with tissue or mechanical valves. RESULTS: Baseline risk profiles generally were better for mechanical valves, and age was the most significant multivariable predictor of late mortality [hazard ratio = 1.4 per 10-year increment, Wald χ(2) = 32.7, p < 0.0001]. As compared with repair, risk-adjusted survival was inferior with either tissue valves [1.8, 27.6, <0.0001] or mechanical valves [1.3, 8.1, 0.0044], and no treatment interaction was observed with age (p = 0.18). At no patient age did tissue valves achieve equivalent survival to either repair or mechanical valves. CONCLUSIONS: Mitral repair is associated with better survival than valve replacement across the spectrum of patient age. If replacement is required, mechanical valves achieve better outcomes, even in the elderly. These data suggest that tissue valves should be reserved only for patients with absolute contraindications to anticoagulation who are not amenable to repair.
Authors: Michele Di Mauro; Gabriele Di Giammarco; Giuseppe Vitolla; Marco Contini; Angela L Iacò; Antonio Bivona; Luca Weltert; Antonio M Calafiore Journal: Ann Thorac Surg Date: 2006-06 Impact factor: 4.330
Authors: Bruno Chiappini; Alvaro Sanchez; Philippe Noirhomme; Robert Verhelst; Jean Rubay; Alain Poncelet; Jean Christophe Funken; Gebrine El Khoury Journal: J Heart Valve Dis Date: 2006-09
Authors: J Scott Rankin; Ricardo E Orozco; Tracey L Rodgers; David D Alfery; Donald D Glower Journal: Ann Thorac Surg Date: 2006-04 Impact factor: 4.330
Authors: Frank Langer; Filiberto Rodriguez; Allen Cheng; Saskia Ortiz; Tom C Nguyen; Mary K Zasio; David Liang; George T Daughters; Neil B Ingels; D Craig Miller Journal: J Thorac Cardiovasc Surg Date: 2006-03-02 Impact factor: 5.209
Authors: S Chauvaud; V Jebara; J C Chachques; B el Asmar; S Mihaileanu; P Perier; G Dreyfus; J Relland; J P Couetil; A Carpentier Journal: J Thorac Cardiovasc Surg Date: 1991-08 Impact factor: 5.209
Authors: Gorav Ailawadi; Brian R Swenson; Micah E Girotti; Leo M Gazoni; Benjamin B Peeler; John A Kern; Lynn M Fedoruk; Irving L Kron Journal: Ann Thorac Surg Date: 2008-07 Impact factor: 4.330
Authors: James S Gammie; Shubin Sheng; Bartley P Griffith; Eric D Peterson; J Scott Rankin; Sean M O'Brien; James M Brown Journal: Ann Thorac Surg Date: 2009-05 Impact factor: 4.330
Authors: J Scott Rankin; Ricardo E Orozco; Theodore R Addai; Tracey L Rodgers; Robert H Tuttle; Lind K Shaw; Donald D Glower Journal: J Heart Valve Dis Date: 2004-05
Authors: Alexander A Brescia; Tessa M F Watt; Liza M Rosenbloom; Shannon L Murray; Xiaoting Wu; Matthew A Romano; Steven F Bolling Journal: J Thorac Cardiovasc Surg Date: 2020-03-05 Impact factor: 6.439
Authors: Ana López-de-Andrés; Javier de Miguel-Díez; Nuria Muñoz-Rivas; Valentín Hernández-Barrera; Manuel Méndez-Bailón; José M de Miguel-Yanes; Rodrigo Jiménez-García Journal: Cardiovasc Diabetol Date: 2019-05-10 Impact factor: 9.951
Authors: Alexander A Brescia; Michael J Paulsen; Tessa M F Watt; Liza M Rosenbloom; Alexander M Wisniewski; Jun Li; Guihua Wang; Donald S Likosky; Wallace J Hopp; Steven F Bolling Journal: Ann Thorac Surg Date: 2020-07-18 Impact factor: 4.330
Authors: Francesco Nicolini; Andrea Agostinelli; Antonella Vezzani; Tullio Manca; Filippo Benassi; Alberto Molardi; Tiziano Gherli Journal: Biomed Res Int Date: 2014-04-10 Impact factor: 3.411